Public listed companies - Open Access .click

Results 251 to 260 of about 63,621 (308)

Corporate Governance and Workplace Mental Health Practices: The Mediating Role of Structured Occupational Safety and Health Engagement. [PDF]

Saf Health Work
Lin RT +4 more
europepmc +1 more source

Strategic Delay and Bargaining Over Public Insurance Coverage for Drugs in Australia. [PDF]

Health Econ
Li JJ, Harris A.
europepmc +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source

A portrait of commissioned literature: connecting the dots between medical education and communication companies, authors, funders and publishers. [PDF]

Res Integr Peer Rev
Bernisson M.
europepmc +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić +4 more
wiley +1 more source

Administrative embedding and employee health protection in China. [PDF]

Front Public Health
Meng X, Wang Y.
europepmc +1 more source

Through the lens of marketing authorization holders: experience in use of real‐world data and real‐world evidence in drug development and regulatory submissions in EU

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola +5 more
wiley +1 more source

Impact of China's national drug price negotiation on pharmaceutical firms' innovation activities. [PDF]

Front Public Health
Xu H, Wang J, Zhou Q.
europepmc +1 more source

Practice, knowledge and attitude of physicians and pharmacists towards the spontaneous reporting system of adverse drug reactions in Switzerland

British Journal of Clinical Pharmacology, EarlyView.
Introduction Introduction Reporting adverse drug reactions (ADRs) is essential for detecting drug risks. Despite legal obligations in Switzerland, underreporting remains an issue. This study assessed practice, knowledge and attitudes towards the spontaneous ADR reporting system among physicians and pharmacists.
Fiona A. Strobel +2 more
wiley +1 more source

Editorial: Volume 2: real world evidence (RWE): paths to enhancing patient access to new medications. [PDF]

J Pharm Pharm Sci
Wills A, Lau CY.
europepmc +1 more source

8. economic growth
1. no poverty
corporate governance

16. peace & justice
financial distress
governance

9. industry and infrastructure
corporate social responsibility
public ownership